To identify risk factors for ticagrelor-induced dyspnea by testing plasma concentrations of ticagrelor and its active metabolite, along with other clinical factors.
Approach:
Key Findings:
Compared with the non-dyspnea group, LDH levels decreased markedly in patients who developed dyspnea (OR=0.814 per 10 U/L, P = 0.027).
The ticagrelor metabolite ratio (TMR) also decreased in the dyspnea group (OR=0.523 per 0.1 increase, P = 0.008).
Peak ticagrelor concentration was higher in the dyspnea group (OR=1.173 per 100 ng/mL, P = 0.012).
The plasma peak concentration of ticagrelor was negatively related to LDH (r = −0.316, P = 0.001).
Interpretation:
The peak concentration of ticagrelor, plasma LDH level, and the TMR are associated with ticagrelor-induced dyspnea in ACS patients.
Limitations:
The study was conducted at a single center, which may limit generalizability.
The sample size was relatively small, with only 23 patients experiencing dyspnea.
Conclusion:
Monitoring plasma concentrations of ticagrelor and its metabolite may be relevant in assessing dyspnea risk.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
